U.S. Markets open in 5 hrs 13 mins

Heat Biologics, Inc. (HTBX)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Add to watchlist
0.52+0.00 (+0.17%)
At close: 3:59PM EDT
People also watch
NVCNEVOKEBIOIMNPSKLN

Heat Biologics, Inc.

801 Capitola Drive
Durham, NC 27713
United States
919-240-7133
http://www.heatbio.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees19

Key Executives

NameTitlePayExercisedAge
Mr. Jeffrey Alan Wolf J.D.Founder, Chairman, Chief Exec. Officer, Pres and Treasurer607.08kN/A54
Ms. Ann A. Rosar M.B.A.VP of Fin. & Corp. Sec.232.39kN/A65
Dr. Jeff T. Hutchins Ph.D.Chief Scientific OfficerN/AN/A58
Dr. Justin Stebbing M.D., M.A., FRCP, FRCPath, Ph.D.Chief Medical Advisor and Member of Scientific & Clinical Advisory BoardN/AN/AN/A
Colonel George E. Peoples Jr.,M.D., FACSChief Medical OfficerN/AN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Heat Biologics, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel allogeneic therapies for a range of cancers and infectious diseases in the United States. The company develops its products based on T cell-stimulating platform technologies, including immune pan-antigen cytotoxic therapy, a platform technology designed to educate and stimulate the immune system against specific disease targets, such as cancer cells; and combination pan-antigen cytotoxic therapy, a platform technology that combines a pan-antigen T cell activating vaccine and a T cell co-stimulator in a single product. Its product candidates include HS-110 that is in Phase 2 clinical trials for the treatment of non-small cell lung cancer; and HS-410, which is in Phase 2 clinical trials for the treatment of non-muscle invasive bladder cancer. The company was founded in 2008 and is based in Durham, North Carolina.

Corporate Governance

Heat Biologics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.